Literature DB >> 15200266

Expression of cyclooxygenase-2 in canine epithelial nasal tumors.

Miriami Kleiter1, David E Malarkey, David E Ruslander, Donald E Thrall.   

Abstract

Cyclooxygenase-2 (COX-2) is an enzyme upregulated in some human and animal tumors. Enzymatic products are associated with tumorigenic activities. Given the poor response of canine nasal tumors to radiation, we considered the possibility that some of this resistance may be associated with COX-2 expression. To test this, 21 formalin-fixed, paraffin-embedded, and archived biopsy samples from canine epithelial nasal tumors were analyzed for COX-2 expression using immunohistochemistry. The biopsies were collected from dogs prior to radiation therapy. COX-2 expression was present in 17 of 21 (81%) tumors. The expression was observed in several different tumor types, including nasal carcinomas, adenocarcinomas, and squamous cell carcinomas. Samples from five control dogs without nasal neoplasia were also analyzed for COX-2 staining. These specimens were characterized by varying degrees of lymphoplasmacytic rhinitis with scattered regions of COX-2 positive respiratory epithelial and stromal cells. Whether the intensity and distribution of COX-2 expression in nasal tumors can be used as a prognostic marker requires further investigation. A combination therapy of irradiation and a selective COX-2 inhibitor appears worthy of clinical investigation in the treatment of canine epithelial nasal tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15200266     DOI: 10.1111/j.1740-8261.2004.04046.x

Source DB:  PubMed          Journal:  Vet Radiol Ultrasound        ISSN: 1058-8183            Impact factor:   1.363


  2 in total

1.  Comparison of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) immunohistochemical expression and outcomes in canine nasal carcinomas treated with radiation therapy.

Authors:  Dah-Renn Fu; Tsuyoshi Kadosawa
Journal:  J Vet Med Sci       Date:  2022-07-15       Impact factor: 1.105

2.  In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation.

Authors:  Blanca Lorenzo-Veiga; Patricia Diaz-Rodriguez; Carmen Alvarez-Lorenzo; Thorsteinn Loftsson; Hakon Hrafn Sigurdsson
Journal:  Nanomaterials (Basel)       Date:  2020-04-09       Impact factor: 5.076

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.